Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Cemiplimab Approved in Europe for PD-L1+ NSCLC, Basal Cell Carcinoma

June 25th 2021

The European Commission has granted approval to cemiplimab for the treatment of patients with locally advanced or metastatic non–small cell lung cancer whose tumor cells have at least 50% PD-L1 expression and no EGFR, ALK, or ROS1 aberrations and are ineligible for definitive chemoradiation.

Dr. Tawbi on the Safety Profile of Relatlimab Plus Nivolumab in Advanced Melanoma

June 24th 2021

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in advanced melanoma.

Novel Targets Set to Add to Checkpoint Blockade Success in Merkel Cell Carcinoma

June 15th 2021

James A. DeCaprio, MD, discusses the incidence of Merkel cell carcinoma, risk factors for the disease, established treatment options, and investigational regimens on the horizon.

Patel Previews Collaborative Research Program With SD-101 in Uveal Melanoma

June 10th 2021

Dr. Patel discusses the significance of the new collaboration between The University of Texas MD Anderson Cancer Center and TriSalus™ Life Sciences.

Alrizomadlin/Pembrolizumab Induces Early Efficacy in Unresectable Melanoma or Advanced Solid Tumors

June 8th 2021

The addition of alrizomadlin to pembrolizumab yielded promising preliminary efficacy and was tolerable in patients with unresectable or metastatic melanoma or advanced solid tumors that have been resistant to immunotherapy agents.

Lenvatinib/Pembrolizumab Yields Continuing Efficacy in Advanced Melanoma

June 6th 2021

Lenvatinib and pembrolizumab continued to yield meaningful and durable responses in patients with advanced melanoma who had progressed on previous PD-L1 inhibitor treatment.

Lifileucel Continues to Demonstrate Durable Responses in Heavily Pretreated Advanced or Metastatic Melanoma

June 6th 2021

Lifileucel has demonstrated promising long-term responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed following PD-1 and PD-L1 inhibition.

Nivolumab Alone, With Ipilimumab Maintains Improved Outcomes in Advanced Melanoma in Long-Term Follow-Up

June 6th 2021

Nivolumab monotherapy, or in combination with ipilimumab, continued to demonstrate durable improvements in overall survival compared with ipilimumab alone in patients with previously untreated advanced melanoma.

Improved Responses Sustained With Pembrolizumab in Treatment-Naïve Melanoma, But Not in Rechallenged Patients

June 6th 2021

Patients with stage III melanoma who progressed following placebo-based treatment in the first part of the phase 3 EORTC 1325/KEYNOTE-054 trial and crossed over to receive pembrolizumab post-recurrence derived a 38.8% overall response rate and a 32% overall 3-year progression-free survival rate.

Dr. Tawbi on the Efficacy of Relatlimab/Nivolumab in Advanced Melanoma

June 6th 2021

Hussein A. Tawbi, MD, PhD, discusses the efficacy of relatlimab plus nivolumab in patients with advanced melanoma.

Lifileucel/Pembrolizumab Elicits Encouraging ORR in ICI-Naïve Advanced Melanoma

June 4th 2021

The addition of lifileucel to pembrolizumab resulted in an overall response rate of 85.7% compared with pembrolizumab alone in patients with immune checkpoint inhibitor–naïve advanced melanoma.

Cosibelimab Under Investigation in Metastatic Cutaneous Squamous Cell Carcinoma

June 1st 2021

The anti–PD-L1, fully human monoclonal antibody cosibelimab will be examined in a cohort of patients with metastatic cutaneous squamous cell carcinoma as part of an ongoing phase 1 study.

Scratching Beneath the Surface in Merkel Cell Carcinoma

May 31st 2021

Due to its rarity, there will likely never be a television advertisement for Merkel cell carcinoma. Yet, several opportunities to help raise awareness and conduct an array of clinical trials are building, due to the disease’s response to checkpoint blockade.

Vidutolimod/Nivolumab Under Evaluation in PD-1–Refractory Advanced Melanoma

May 30th 2021

The safety and efficacy of the combination of vidutolimod and nivolumab is currently under investigation in patients with PD-1–refractory advanced melanoma.

Baumann Characterizes the Current Treatment Landscape of Merkel Cell Carcinoma

May 27th 2021

Dr. Baumann sheds light on the incidence, prognosis, and treatment of patients with Merkel cell carcinoma, ongoing clinical research, and strategies to raise awareness for this rare disease.

Immune-Based Combination Regimens Play a Growing Role in MCC

May 27th 2021

Merkel cell carcinoma is a rare, highly aggressive skin tumor associated with the Merkel cell polyomavirus infection, which has been detected in nearly 80% of MCC diagnoses.

Dr. DeCaprio on Raising Awareness in Merkel Cell Carcinoma

May 25th 2021

James A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.

Dr. D’Angelo on the Incidence and Prognosis of Merkel Cell Carcinoma

May 25th 2021

Sandra P. D’Angelo, MD, discusses the incidence and prognosis of patients with Merkel cell carcinoma.

UCSD Faculty Contextualize Cases of Cutaneous Squamous Cell Carcinoma

May 20th 2021

Drs Park, Daniels, Sanghvi, and Kolb, discuss two high-risk non-melanoma skin cancer cases and highlighted patient and tumor risk factors to consider in the clinical setting.

Dr. Johnson on the Rationale for Examining Chronic irAEs Associated With Anti-PD-1 Therapy in Melanoma

May 20th 2021

Douglas B. Johnson, MD, discusses the rationale for examining chronic immune-related adverse effects associated with anti–PD-1 therapy in patients with high-risk resected melanoma.